Sushilkumar Satish Gupta1, Charalampos S Floudas2, Abhinav B Chandra3. 1. Department of Pulmonary and Critical Care Medicine, Maimonides Medical Center, Brooklyn, New York, USA. 2. Department of Internal Medicine, Maimonides Medical Center, Brooklyn, New York, USA. 3. Department of Hematology and Oncology, Yuma Regional Medical Center Cancer Center, Yuma, Arizona, USA.
Abstract
BACKGROUND: Malignant pleural effusion (MPE) is a common cause of quality of life deterioration in patients with advanced cancer. Management options include chemical pleurodesis with a sclerosing agent such as doxycycline or talc powder, surgery, and also the placement of tunneled indwelling pleural catheters (IPCs). Two different IPC types are mostly used in the USA. METHODS: We conducted a single-center retrospective study with the objective to compare the efficacy and safety profiles of two IPC systems. Patients with a diagnosis of malignancy, who received IPCs by the interventional radiology department of our hospital from January 2013 to March 2015, were identified in the local database and a chart review was performed to record characteristics and outcomes. Patients without a diagnosis of malignancy or with pleural effusions of cardiac origin were excluded from the study. RESULTS: We identified 27 patients with a median age of 59.0 years. Eighty patients received Aspira catheter while nine patients received PleurX catheter, and seven patients achieved spontaneous pleurodesis. The median length of stay (LOS) was 9 days for the Aspira group (AG), as compared to 13 days for the PleurX group (PG) (overall median LOS was 10 days; range, 2-62 days). The rate of catheter-related complications (pain, obstruction, loculations, infection, hemorrhage) was 39% (seven patients) for the AG and 33% (three patients) for the PG (overall ten patients, 37%). CONCLUSIONS: In our study, outcomes and safety were similar for patients receiving either type of IPC, Aspira or PleurX.
BACKGROUND: Malignant pleural effusion (MPE) is a common cause of quality of life deterioration in patients with advanced cancer. Management options include chemical pleurodesis with a sclerosing agent such as doxycycline or talc powder, surgery, and also the placement of tunneled indwelling pleural catheters (IPCs). Two different IPC types are mostly used in the USA. METHODS: We conducted a single-center retrospective study with the objective to compare the efficacy and safety profiles of two IPC systems. Patients with a diagnosis of malignancy, who received IPCs by the interventional radiology department of our hospital from January 2013 to March 2015, were identified in the local database and a chart review was performed to record characteristics and outcomes. Patients without a diagnosis of malignancy or with pleural effusions of cardiac origin were excluded from the study. RESULTS: We identified 27 patients with a median age of 59.0 years. Eighty patients received Aspira catheter while nine patients received PleurX catheter, and seven patients achieved spontaneous pleurodesis. The median length of stay (LOS) was 9 days for the Aspira group (AG), as compared to 13 days for the PleurX group (PG) (overall median LOS was 10 days; range, 2-62 days). The rate of catheter-related complications (pain, obstruction, loculations, infection, hemorrhage) was 39% (seven patients) for the AG and 33% (three patients) for the PG (overall ten patients, 37%). CONCLUSIONS: In our study, outcomes and safety were similar for patients receiving either type of IPC, Aspira or PleurX.
Entities:
Keywords:
Aspira; PleurX; cancer; end of life; indwelling pleural catheter (IPC); malignant pleural effusion (MPE); palliative
Authors: Todd L Demmy; Lin Gu; Jack E Burkhalter; Eric M Toloza; Thomas A D'Amico; Susan Sutherland; Xiaofei Wang; Laura Archer; Linda J Veit; Leslie Kohman Journal: J Natl Compr Canc Netw Date: 2012-08 Impact factor: 11.908
Authors: J B Putnam; R W Light; R M Rodriguez; R Ponn; J Olak; J S Pollak; R B Lee; D K Payne; G Graeber; K L Kovitz Journal: Cancer Date: 1999-11-15 Impact factor: 6.860
Authors: Pranav Murthy; Chigozirim N Ekeke; Kira L Russell; Samuel C Butler; Yue Wang; James D Luketich; Adam C Soloff; Rajeev Dhupar; Michael T Lotze Journal: Oncoimmunology Date: 2019-01-22 Impact factor: 8.110